The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT (NCT05923814) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-07 |
Track The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT automatically
Every clearance here is in the API, with alerts when new ones post.